论文部分内容阅读
目的比较参芪扶正注射液联合化疗治疗与单纯化疗治疗中晚期肺癌的的临床疗效和不良反应。方法回顾分析76例中晚期肺癌患者治疗情况,其中采用参芪扶正注射液联合GP方案化疗39例为治疗组,单纯GP方案治疗37例为对照组。结果治疗组和对照组总有效率(CR+PR)分别为66.67%、54.05%(χ2=6.48,P<0.05)。治疗组治疗后T淋巴细胞亚群CD4/CD8比值(2.58±0.15vs3.76±0.23,P<0.05)有明显提高;对照组治疗后CD4/CD8比值降低(2.38±0.12vs1.76±0.32,P<0.05)。生活质量治疗组高于对照组(P<0.05);恶心呕吐反应及白细胞减少情况治疗组低于对照组(P<0.05)。结论参芪扶正注射液联合化疗治疗能提高中晚期肺癌化疗有效率、减轻化疗后恶心呕吐反应及白细胞减少、降低化疗对中晚期肺癌患者免疫功能的影响、提高生活质量。
Objective To compare the clinical efficacy and adverse reactions of Shenqi Fuzheng Injection combined with chemotherapy and chemotherapy alone in the treatment of advanced lung cancer. Methods A retrospective analysis of 76 patients with advanced lung cancer treatment, including the use of Shenqi Fuzheng injection combined with GP regimen chemotherapy in 39 cases, the simple GP regimen in 37 cases as control group. Results The total effective rate (CR + PR) of the treatment group and the control group were 66.67% and 54.05%, respectively (χ2 = 6.48, P <0.05). After treatment, the CD4 / CD8 ratio of T lymphocyte subsets (2.58 ± 0.15 vs 3.76 ± 0.23, P <0.05) was significantly increased in treatment group. The CD4 / CD8 ratio of control group decreased after treatment (2.38 ± 0.12 vs 1.76 ± 0.32, P <0.05). The quality of life in the treatment group was higher than that in the control group (P <0.05). The nausea and vomiting reaction and leukopenia in the treatment group were lower than those in the control group (P <0.05). Conclusion Shenqi Fuzheng injection combined with chemotherapy can improve the efficiency of chemotherapy for advanced lung cancer, reduce the nausea and vomiting reaction and leukopenia after chemotherapy, reduce the impact of chemotherapy on the immune function of patients with advanced lung cancer, and improve the quality of life.